In patients with connective tissue disease, vascular injury induced by primary or secondary vasculitis syndromes can lead to organ dysfunction due to the loss of nutrient supply from the blood. Such vasculitis syndromes can be refractory to treatment and (Table 1) . 2 This review provides an overview of this new nomenclature.
| INTRODUCTION
. 2 This review provides an overview of this new nomenclature.
| CONCEPT OF VASCULITIS SYNDROME FOR DIAGNOSIS
The pathophysiologic basis of the clinical features of primary vasculitis is related to the fact that blood vessels supply oxygen to maintain the function of solid organs and the interstitium. As a result of inflammation in blood vessels, bleeding caused by the breakdown of vascular structures (secondary to inflammation) or interruption of blood flow can lead to organ dysfunction. This occurs in the local area of the vasculitic lesion as well as in the visceral organs and interstitium in the peripheral perfusion area.
With regard to diagnosis of primary vasculitis syndrome, it is important to systematize individual localized symptoms, which, at first glance, appear to be independent. The clinician should assess whether or not such individual localized symptoms are the results of ischemia caused by the inflammation of blood vessels or due to symptoms that arise as a result of bleeding. Hence, rather than keeping a diagnosis of subdivided individual vasculitis in mind, it is more important for clinicians to understand the diagnostic process of the vasculitis syndrome ( Figure 1 ) and the clinical symptoms of vasculitis.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The disease that a nomenclature was changed to (New nomenclatures are expressed in a bold-face.) Revised from reference 2.
| DIAGNOSIS OF VASCULITIS SYNDROMES
Clinical features of primary vasculitis syndromes can be classified largely into two categories: systemic signs/symptoms caused by inflammation and localized visceral signs/symptoms specific to the affected organs (Table 2) . 3 Signs/symptoms that could evoke the possibility of vasculitis syndrome are described as follows.
| Systemic manifestations
1. Fever of unknown origin (FUO): In many cases, the patient experiences a high, spiking fever of 38-39°C.
Weight loss caused by inflammation.
3. Weakness, general malaise. The aforementioned systemic symptoms are frequently seen among elderly people with malignant tumors. Therefore, during the process of diagnosis for vasculitis syndrome, it is recommended to also conduct screening examinations for malignant tumors. 
| Local symptoms
Local symptoms are featured by the simultaneous (or sequential) appearance of symptoms from different affected organs in a patient with vasculitis syndrome.
1.
Visceral Signs/Symptoms of Large-and Medium-Vessel Vasculitis.
As large to medium-sized blood vessels run from the aorta to the organs, the signs/symptoms of vasculitis result from injury to organs supplied by the affected vessels. angiography. However, aneurysms are usually not detected during the acute phase. In some cases, it is possible to detect impaired blood flow using MRA or the ultrasonic Doppler method. However, in Japan, some physicians tend to avoid conventional angiography because of its invasiveness and because PAN can typically be diagnosed via biopsy.
Physiological tests: electrocardiography (ECG), pulse-wave detection, electroencephalography (EEG), electromyography (EMG), and
nerve conduction studies are important for the diagnosis of vasculitis syndrome and to classify its severity. EMG and nerve conduction studies are crucial for the diagnosis of latent vasculitis syndrome and to identify appropriate biopsy sites.
| Tissue biopsy
With regard to small-vessel vasculitis, it is essential to test for ANCA and immune complexes. However, these are definitive factors for diagnosis; rather, tissue biopsy is the most important diagnostic Since use of these drugs for Takayasu arteritis is not indicated in Japan, physicians should obtain adequate informed consent from patients when using for therapy.
process, some patients may experience worsening in their condition. Therefore, in cases of vasculitis syndrome, rapid testing and treatment is necessary, hospitalization should be considered to increase the speed of this process. Further, referral or transfer to specialized centers is highly recommended if vasculitis syndrome is suspected.
| TREATMENT OF VASCULITIS
To prevent irreversible organ failure caused by the progression of vasculitis, it is important to use immunosuppressant drugs to reduce inflammation as soon as possible. It is also critical to maintain blood flow through the affected vessels.
In most cases, the first-line drug for the treatment of vasculitis syndrome is a corticosteroid. Some of the treatment methods for typical vasculitis syndrome are listed below:
| Treatment of large-vessel vasculitis
Corticosteroid is effective for most patients with TAK and GCA. Strong anti-inflammatory effect has enabled a physician to begin administration with steroids in the early stages of the disease. However, some cases of vasculitis are resistant to corticosteroids. Therefore, attempts have been made to develop new methods of treatment using immunosuppressants to control such cases of steroid-resistant vasculitis (Figure 2 ). 
| Treatment for medium-vessel vasculitis
Polyarteritis nodosa is the representative medium-vessel vasculitis.
Based on the classification of vasculitis syndrome by the CHCC in 1994, MPA was separated from PAN. Since then, the number of reported cases of PAN has decreased. The response to corticosteroid therapy is better with PAN than with MPA. However, in patients with organ failure, combination therapy with immunosuppressive agents is desirable (Figure 3 ). 
| Treatment for small-vessel vasculitis
Microscopic polyangiitis is a representative of small-vessel vasculitis with necrotizing angiitis of small vessels (capillaries and arterioles).
In many cases, lungs and kidneys are the major target organs. The incidence of ANCA positivity is high (~80%) in patients with MPA.
In Japan, cases of MPO-ANCA are more predominant than those of PR3-ANCA. 12 In or treatment with the anti-CD20 antibody, rituximab, 16 in GPA or MPA that is resistant to the standard therapy with cyclophosphamide and corticosteroids) are permitted under the medical care insurance system.
Vasculitis syndrome is a rare disease of unknown etiology. In addition to advances in knowledge regarding the pathogenesis of vasculitis, we believe that large multicenter clinical trials in Japan could help define the etiology and optimal treatment for vasculitis syndrome.
